1. The prognostic and clinical value of p53 upregulated modulator of apoptosis expression in solid tumors: a meta-analysis and TCGA data review
- Author
-
Weifeng Gao, Zhen Yuan, Xuanzhu Zhao, Shuyuan Wang, Sizhen Lai, Kemin Ni, Yixiang Zhan, Zhaoce Liu, Lina Liu, Ran Xin, Xin Yin, Xingyu Zhou, Xinyu Liu, Xipeng Zhang, Qinghuai Zhang, Guoxun Li, Wenhong Wang, and Chunze Zhang
- Subjects
Neoplasms ,Genetics ,Biomarkers, Tumor ,Molecular Medicine ,Humans ,Apoptosis ,Tumor Suppressor Protein p53 ,Prognosis ,Molecular Biology ,Pathology and Forensic Medicine - Abstract
Previous studies have reported the prognostic value of p53 upregulated modulator of apoptosis (PUMA) in numerous human tumors, but the conclusions have not been consistent. Therefore, this meta-analysis and the Cancer Genome Atlas (TCGA) data analysis were performed to estimate the prognostic significance of PUMA in solid tumors. A search was conducted in PubMed, Embase, Web of Science, Cochrane Library and CNKI up to 21 July 2022. In total, 10 studies with 2,207 patients were included. We extracted the overall survival (OS) and disease-free survival (DFS) data. The hazard ratios (HRs) and 95% confidence intervals (95% CI) were adopted for evaluating the association. Decreased PUMA expression was significantly associated with worse OS (HR = 0.54, 95% CI = 0.38–0.78) and worse DFS (HR = 0.54, 95% CI = 0.42–0.70). Subgroup analysis showed that the prognostic role of PUMA for OS was most significant in the digestive system (HR = 0.52, 95% CI = 0.38–0.69). Furthermore, the expression of PUMA was not affected by tumor differentiation or clinical stage, and TCGA dataset analysis confirmed these results. We proved that expression of PUMA may serve as an independent prognostic factor for patients with solid tumors.
- Published
- 2022